NL-OMON36630
Completed
Not Applicable
Study of the Safety, Tolerability, Pharmacokinetics and Effect on Renal Potassium Clearance after Multiple Oral Dosing of LY2623091 in Healthy Volunteers - LY2623091 MAD study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- chronic kidney disease
- Sponsor
- Eli Lilly
- Enrollment
- 32
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- Healthy males and/or healthy females (postmenopausal/sterilized)
- •\- 18\-65 years, inclusive
- •\- BMI: 19\.0\-32\.5 kg/m2, inclusive
- •\- non\-smoking, or smoking a maximum of10 cigarettes/day
Exclusion Criteria
- •Suffering from: hepatitis B, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1\.5 liters of blood (for men) / more than 1\.0 liters of blood (for women) in the 10 months prior the start of this study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Study of Safety, Tolerability, and Pharmacokinetics of BG00010 (Neublastin) Intravenous and Subcutaneous Single Ascending Doses in Healthy Volunteers, and Subcutaneous Multiple Ascending Doses in Subjects with Painful Lumbar Radiculopathylow back painPainful Lumbar Radiculopathy10041543NL-OMON40320Biogen Idec78
Completed
Not Applicable
Study of the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple oral dosing in healthy subjects including brain Serotonin Transporter (SERT) occupancy by Positron Emission Tomography (PET).chronische pijn aan beschadigde organen.visceral painNL-OMON34068Eli Lilly51
Completed
Not Applicable
Study of the Safety, Tolerability and Pharmacokinetics of LY2623091 after Single Oral Dosing in Healthy SubjectsNL-OMON34283Chorus LRL (Division of Eli Lilly)18
Completed
Not Applicable
A Safety, Tolerability and Pharmacokinetic Study of Single and Multiple Doses of LY3526318 in Healthy ParticipantsNL-OMON50998Eli Lilly16
Active, not recruiting
Phase 1
Safety, Tolerability and Pharmacokinetics of Tirzepatide in Pediatric Participants with Obesity.Weight managementMedDRA version: 20.0Level: HLTClassification code 10027428Term: Metabolic disorders NECSystem Organ Class: 100000004861Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]EUCTR2024-000081-22-Outside-EU/EEAEli Lilly and Company